Rockville, MD-based Sucampo Pharmaceuticals is a global biopharmaceutical company which currently has one marketed product, Amitiza, in its portfolio. Amitiza is approved for chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) among adult women and opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
{iframe}http://www.nasdaq.com/article/sucampo-scmp-remains-focused-on-amitza-label-expansion-cm812142{/iframe}